ResearcherTongji HospitalNo recent work listed

Xu Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3210-1274; OpenAlex author ID A5100342446. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 6

Papers, trials and grants by year

2015: 1 paper

Papers 1

Synergistic antitumor activity of withaferin A combined with oxaliplatin triggers reactive oxygen species-mediated inactivation of the PI3K/AKT pathway in huma… Co-author DOI 10.1016/j.canlet.2014.11.026 ↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Xin Wang · 1 shared paper, 2015 · strength 0.04
- Paper Synergistic antitumor activity of withaferin A combined with oxaliplatin triggers reactive oxygen species-mediated inac… DOI 10.1016/j.canlet.2014.11.026 ↗
Chengyi Sun · 1 shared paper, 2015 · strength 0.04
- Paper Synergistic antitumor activity of withaferin A combined with oxaliplatin triggers reactive oxygen species-mediated inac… DOI 10.1016/j.canlet.2014.11.026 ↗
Xingjun Guo · 1 shared paper, 2015 · strength 0.04
- Paper Synergistic antitumor activity of withaferin A combined with oxaliplatin triggers reactive oxygen species-mediated inac… DOI 10.1016/j.canlet.2014.11.026 ↗
Chengjian Shi · 1 shared paper, 2015 · strength 0.04
- Paper Synergistic antitumor activity of withaferin A combined with oxaliplatin triggers reactive oxygen species-mediated inac… DOI 10.1016/j.canlet.2014.11.026 ↗
Jianxin Jiang · 1 shared paper, 2015 · strength 0.04
- Paper Synergistic antitumor activity of withaferin A combined with oxaliplatin triggers reactive oxygen species-mediated inac… DOI 10.1016/j.canlet.2014.11.026 ↗
Renyi Qin · 1 shared paper, 2015 · strength 0.04
- Paper Synergistic antitumor activity of withaferin A combined with oxaliplatin triggers reactive oxygen species-mediated inac… DOI 10.1016/j.canlet.2014.11.026 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.